A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.… Read more
Experts reveal pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery, according to a phase 3 study being presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.… Read more
Doubling treatment duration of bevacizumab did not lead to better survival in patients with ovarian cancer who were treated on a phase 3 trial.
For patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, prolonged treatment
By Jennifer Southall
The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical Oncology… Read more
No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab.
By Charles Bankhead
An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.… Read more
Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more
Results of quality of life (QoL) assessments from the randomized, phase 3 ICON8 study evaluating once-weekly vs thrice-weekly administration of paclitaxel in combination with carboplatin as first-line chemotherapy in patients with epithelial ovarian cancer do … Read more
By Liam Davenport
Women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation could see their survival extended by over a year by maintenance therapy with the PARP-inihibitor olaparib (Lynparza, AstraZeneca).
The new overall survival (OS) data come … Read more
NEW YORK – The US Food and Drug Administration has approved olaparib (AstraZeneca/Merck’s Lynparza) in combination with bevacizumab (Genentech’s Avastin) as a maintenance regimen for advanced ovarian cancer patients who have homologous recombination deficiency (HRD) and are responding to first-line … Read more
By Beth Fand Incollingo
The Food and Drug Administration (FDA) has approved the combination of two targeted drugs, Lynparza (olaparib) and Avastin (bevacizumab), for patients with advanced ovarian cancer who have responded to initial treatment with platinum-based chemotherapy plus Avastin … Read more
By Hannah Slater
The FDA approved niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.1
Efficacy for … Read more
By Gina Columbus
Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II … Read more
By Gina Columbus
The combination of olaparib (Lynparza) and bevacizumab (Avastin) was found to improve progression-free survival (PFS) outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the … Read more
By Jason M. Broderick
Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.1
The 3-arm … Read more
By Pam Harrison
Uptake of neoadjuvant chemotherapy (NAC) for the treatment of advanced ovarian cancer has increased dramatically since 2006 in the United States, but importantly, the median survival has also continued to increase, new research shows.
These trends confirm … Read more
By Gina Columbus
Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival (RFS) compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease, according to phase II results from the … Read more
By Susan Moench, PhD, PA-C
Preliminary assessments of secondary study endpoints of a phase 3 clinical trial evaluating maintenance therapy with niraparib, an inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP), compared with placebo in patients with newly diagnosed advanced ovarian … Read more
By Susan Moench, PhD, PA-C
An interim analysis of results of the first phase 3 clinical trial evaluating an immune checkpoint inhibitor either in combination with or following platinum-based chemotherapy compared with chemotherapy alone in patients with previously untreated advanced … Read more
By Nichole Tucker
GEN-1 immunotherapy demonstrated dose-dependent efficacy results in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) when treated in combination with the standard of care, according to results from the OVATION 2 … Read more
Rather than hold a walk in San Diego, we invite you to create a Team, invite friends and family to join and gather to fun-raising and raise funds, wherever you are.
